語系:
繁體中文
English
說明(常見問題)
回圖書館首頁
手機版館藏查詢
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Using Lean Practices to Reduce Cost ...
~
Wang, Chao-Kuei.
FindBook
Google Book
Amazon
博客來
Using Lean Practices to Reduce Cost and Lead Time for the Autologous CAR-T Cell Manufacturing Process.
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Using Lean Practices to Reduce Cost and Lead Time for the Autologous CAR-T Cell Manufacturing Process./
作者:
Wang, Chao-Kuei.
出版者:
Ann Arbor : ProQuest Dissertations & Theses, : 2020,
面頁冊數:
121 p.
附註:
Source: Dissertations Abstracts International, Volume: 81-05, Section: A.
Contained By:
Dissertations Abstracts International81-05A.
標題:
Engineering. -
電子資源:
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27547114
ISBN:
9781392756911
Using Lean Practices to Reduce Cost and Lead Time for the Autologous CAR-T Cell Manufacturing Process.
Wang, Chao-Kuei.
Using Lean Practices to Reduce Cost and Lead Time for the Autologous CAR-T Cell Manufacturing Process.
- Ann Arbor : ProQuest Dissertations & Theses, 2020 - 121 p.
Source: Dissertations Abstracts International, Volume: 81-05, Section: A.
Thesis (D.Engr.)--The George Washington University, 2020.
This item must not be sold to any third party vendors.
Immune and cell therapies have started to play important roles in cancer treatment. Among different cell therapy methods, Chimeric Antigen Receptors T-cell (CAR-T cell) therapy is the first and only autologous cell therapy that the FDA has approved for cancer treatment so far. CAR-T therapy is a highly customized and novel treatment method that re-engineers a patient's own T-cells to equip the cells with the ability to recognize and attack tumor cells, provoking lesser immune response issues. However, the disadvantage of the autologous CAR-T cell therapy is that each patient's CAR-T cells have to be produced individually to avoid immune response. Hence, the production cost of CAR-T cells is high, and the lead time is long. The newly-invented CliniMACS Prodigy cell automatic processor was developed around 2014 and significantly reduced traditional manual operations in the CAR-T production process. Although Prodigy reduced the number of manual steps and lowered the chance of contamination, it did not reduce the production cost and the lead time remains long. In this study, we introduced Lean principles to the CAR-T production process. We used two Lean tools-Root Cause Analysis (RCA) and Value Stream Mapping (VSM)-to analyze current production process and determine sources of process waste. The simulation results showed that the manufacturing time can be shortened by 11.46% (42.61 hours) by reducing QC test time and production preparation time. For the production cost analysis, our cost of goods (COG) analysis result showed that, after shortening lead time and increase Prodigy system from one to two units to increase productivity, manufacturers could save up to 13.47% of the cost for the process.
ISBN: 9781392756911Subjects--Topical Terms:
586835
Engineering.
Subjects--Index Terms:
Autologous cell therapy
Using Lean Practices to Reduce Cost and Lead Time for the Autologous CAR-T Cell Manufacturing Process.
LDR
:03014nmm a2200397 4500
001
2266081
005
20200608113731.5
008
220629s2020 ||||||||||||||||| ||eng d
020
$a
9781392756911
035
$a
(MiAaPQ)AAI27547114
035
$a
AAI27547114
040
$a
MiAaPQ
$c
MiAaPQ
100
1
$a
Wang, Chao-Kuei.
$3
3543265
245
1 0
$a
Using Lean Practices to Reduce Cost and Lead Time for the Autologous CAR-T Cell Manufacturing Process.
260
1
$a
Ann Arbor :
$b
ProQuest Dissertations & Theses,
$c
2020
300
$a
121 p.
500
$a
Source: Dissertations Abstracts International, Volume: 81-05, Section: A.
500
$a
Advisor: Blackburn, Timothy.
502
$a
Thesis (D.Engr.)--The George Washington University, 2020.
506
$a
This item must not be sold to any third party vendors.
506
$a
This item must not be added to any third party search indexes.
520
$a
Immune and cell therapies have started to play important roles in cancer treatment. Among different cell therapy methods, Chimeric Antigen Receptors T-cell (CAR-T cell) therapy is the first and only autologous cell therapy that the FDA has approved for cancer treatment so far. CAR-T therapy is a highly customized and novel treatment method that re-engineers a patient's own T-cells to equip the cells with the ability to recognize and attack tumor cells, provoking lesser immune response issues. However, the disadvantage of the autologous CAR-T cell therapy is that each patient's CAR-T cells have to be produced individually to avoid immune response. Hence, the production cost of CAR-T cells is high, and the lead time is long. The newly-invented CliniMACS Prodigy cell automatic processor was developed around 2014 and significantly reduced traditional manual operations in the CAR-T production process. Although Prodigy reduced the number of manual steps and lowered the chance of contamination, it did not reduce the production cost and the lead time remains long. In this study, we introduced Lean principles to the CAR-T production process. We used two Lean tools-Root Cause Analysis (RCA) and Value Stream Mapping (VSM)-to analyze current production process and determine sources of process waste. The simulation results showed that the manufacturing time can be shortened by 11.46% (42.61 hours) by reducing QC test time and production preparation time. For the production cost analysis, our cost of goods (COG) analysis result showed that, after shortening lead time and increase Prodigy system from one to two units to increase productivity, manufacturers could save up to 13.47% of the cost for the process.
590
$a
School code: 0075.
650
4
$a
Engineering.
$3
586835
650
4
$a
Management.
$3
516664
650
4
$a
Pharmaceutical sciences.
$3
3173021
653
$a
Autologous cell therapy
653
$a
CAR-T
653
$a
cGMP
653
$a
Lean
653
$a
Manufacturing
653
$a
Value stream mapping
690
$a
0537
690
$a
0454
690
$a
0572
710
2
$a
The George Washington University.
$b
Engineering Management.
$3
1262973
773
0
$t
Dissertations Abstracts International
$g
81-05A.
790
$a
0075
791
$a
D.Engr.
792
$a
2020
793
$a
English
856
4 0
$u
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27547114
筆 0 讀者評論
館藏地:
全部
電子資源
出版年:
卷號:
館藏
1 筆 • 頁數 1 •
1
條碼號
典藏地名稱
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
W9418315
電子資源
11.線上閱覽_V
電子書
EB
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
評論
新增評論
分享你的心得
Export
取書館
處理中
...
變更密碼
登入